Myeloma Paper of the Day, September 14th, suggested by Robert Orlowski

Robert Orlowski shared on X:

“Myeloma Paper of the Day: Myeloma patients with active disease or in remission after therapy have low levels of salivary IgG and IgA antibody levels against Pneumococcus, which may further contribute to infection risk.”

Source: Robert Orlowski/X

Plasma cell disorders supress mucosal anti-bacterial immunity: another dimension of immunoparesis in plasma cell neoplasms

Authors: Sian Faustini, Y. L. Tracey Chan, Lilli Evans, Emily Collman, Alec Rapson, Claire Backhouse, Annabelle Emery, John P. Campbell, Sally Moore, Alex Richter, Guy Pratt, Mark T. Drayson and Jennifer L. J. Heaney.

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.